Abstract: In one aspect of the invention, a dye sensitized solar cell has a counter-electrode including carbon-titania nanocomposite thin films made by forming a carbon-based ink; forming a titania (TiO2) solution; blade-coating a mechanical mixture of the carbon-based ink and the titania solution onto a substrate; and annealing the blade-coated substrate at a first temperature for a first period of time to obtain the carbon-based titania nanocomposite thin films. In certain embodiments, the carbon-based titania nanocomposite thin films may include solvent-exfoliated graphene titania (SEG-TiO2) nanocomposite thin films, or single walled carbon nanotube titania (SWCNT-TiO2) nanocomposite thin films.

Abstract: Provided herein are devices that facilitate the magnetic separation of an analyte from a sample, and methods of use thereof. In particular embodiments, devices and methods are provided for the trans-interfacial magnetic separation (TIMS) of analytes from a sample.

Abstract: Disclosed are methods for methods, compounds, and compositions for treating cancers characterized by therapeutic targeting of the BAP1 histone H2A deubiquitinase (DUB) complex, otherwise referred to herein as the BAP1 complex. In particular, the methods, compounds, and compositions disclosed herein relate to the use of therapeutic agents that inhibit the biological activity of the BAP1 complex for treating cancers such as myeloid neoplasms.

Abstract: Provided herein are methods of preparing tetrahexahedra nanoparticles and methods of using the tetrahexahedra nanoparticles as an oxidative catalyst.

Abstract: Mesoporous zirconium metal-organic frameworks (MOFs) having insulin immobilized therein and methods of using the MOFs in insulin delivery are provided. The insulin-loaded metal-organic framework molecules include a porous zirconium metal-organic framework molecule and insulin molecules within pores of the porous zirconium metal-organic framework.

Abstract: Provided are methods for treating acute and recurring urinary tract infections in dogs.

Abstract: An electronic system for monitoring a physical parameter includes an ADM comprising an accumulation mode sensor for measuring the physical parameter by generating electrical energy associated with the physical parameter in response to a surrounding condition, and an energy storing device coupled to the accumulation mode sensor for accumulatively storing the generated electrical energy; a power source; and an SoC coupling with the ADM and the power source, configured such that the stored electrical energy is monitored, and when the stored electrical energy is equal to or greater than a pre-defined threshold, a wake-up event is generated to trigger the SoC to operates in a run mode in which the physical parameter is wirelessly transmitted to a receiver and the stored electrical energy in the energy storing device is discharged, and then the SoC returns to a sleep mode in which a minimal power is consumed.

Abstract: A molecular imaging agent including a detectable moiety, a chelation moiety, and a carrier moiety is provided. In one embodiment, the detectable moiety is coupled to the chelation moiety and the chelation moiety is linked to the carrier moiety. In another embodiment, the detectable moiety is 99mTc; the chelation moiety includes HYNIC; and the carrier moiety includes from N-terminus to C-terminus: a His6 purification tag, a human VEGFA polybasic tag sequence, and a human Fc stabilization segment.

Abstract: Disclosed are methods for treating a psychiatric disease or disorder and/or symptoms thereof in a subject in need thereof, the method comprising administering to the subject an effective amount of an antagonist of the Na+-K+-2Cl— cation-chloride cotransporter isoform 1 (NKCC1) for treating the psychiatric disorder and/or the symptoms thereof in the subject. The methods further may include administering to the subject a dopamine D1 agonist and/or a GABAA agonist, optionally at a subeffective dose, where co-administering the antagonist of NKCC1 improves the efficacy of the dopamine D1 agonist and/or the GABAA agonist, optionally at the subeffective dose, for treating the psychiatric disease or disorder and/or symptoms thereof.

Abstract: Disclosed are methods and compositions for treating an infection by an enveloped virus in a patient in need thereof. The methods include administering to the patient a compound that inhibits or blocks release of the enveloped virus from an infected cell. As such, the disclosed methods include methods of inhibiting or blocking release of an enveloped virus from a cell. The disclosed methods may include administering to the patient a prazole-type compound having a substituted (pyridin-2-yl)methylsulfinyl-benzimidazole core.

Abstract: A system for evaluating a rigidity of an angle bracket includes a test system having a first test fixture and a second test fixture. The system includes an angle bracket coupon including a first wall, a second wall coupled to the first wall at a bend to define an angle between the first wall and the second wall, and at least one three dimensional feature defined at the bend that extends between the first wall and the second wall. The angle bracket coupon is to be coupled to at least one of the first test fixture and the second test fixture to evaluate the rigidity of the angle bracket.

Abstract: Cathode materials for lithium ion batteries, lithium ion batteries incorporating the cathode materials, and methods of operating the lithium ion batteries are provided. The materials, which are composed of lithium iron oxides, are able to undergo reversible anionic and cationic redox reactions with no O2(g) generation.

Abstract: Systems and methods for integrating genomic results with electronic health records in accordance with embodiments of the invention are disclosed. In one embodiment, a method includes obtaining first raw genetic data formatted in a first format, obtaining second raw genetic data formatted in a second format normalizing the first raw genetic data by substituting at least one symbol in the first raw genetic data, normalizing the second raw genetic data, generating genetic data for the patient by modifying the first raw genetic data by converting the normalized symbols in the first raw genetic data to a common format, modifying the second raw genetic data by converting the normalized symbols in the second raw genetic data to the common format, and generating the genetic data for the patient based on the first raw genetic data and the second raw genetic data, and storing the genetic data.

Abstract: Ink formulations comprising bioactive particles, methods of printing the inks into three-dimensional (3D) structures, and methods of making the inks are provided. Also provided are objects, such as tissue growth scaffolds and artificial bone, made from the inks, methods of forming the objects using 3D printing techniques, and method for growing tissue on the tissue growth scaffolds. The inks comprise a plurality of bioactive ceramic particles, a biocompatible polymer binder, optionally at least one bioactive factor, and a solvent.

Abstract: Superlattices and methods of making them are disclosed herein. The superlattices are prepared by irradiating a sample to prepare an alternating superlattice of layers of a first material and a second material, wherein the ratio of the first deposition rate to the second deposition rate is between 1.0:2.0 and 2.0:1.0. The superlattice comprises a multiplicity of alternating layers, wherein the multiplicity of layers of the first material have a thickness between 0.1 nm and 50.0 nm or the multiplicity of layers of the second material have a thickness between 0.1 nm and 50.0.

Abstract: Methods for forming polyolefin nanocomposite precursor compositions are provided. In embodiments, such a method comprises mixing a polyolefin, unmodified graphite, and a peroxide crosslinker via solid-state shear pulverization under conditions to form a polyolefin nanocomposite precursor composition comprising the polyolefin; exfoliated, unmodified graphite dispersed throughout the polyolefin; and unreacted peroxide crosslinker dispersed throughout the polyolefin, wherein the polyolefin is polyethylene, a copolymer of polyethylene, or combinations thereof. Methods of forming crosslinked polyolefin nanocomposites, the polyolefin nanocomposite precursor compositions, and crosslinked polyolefin nanocomposites are also provided.

Abstract: Diffusion-based and ion implantation-based methods are provided for fabricating planar photodetectors. The methods may be used to fabricate planar photodetectors comprising type II superlattice absorber layers but without mesa structures. The fabricated planar photodetectors exhibit high quantum efficiencies, low dark current densities, and high specific detectivities as compared to photodetectors having mesa structures.

Abstract: Disclosed are chromane compounds, analogs thereof, and methods of their synthesis and use. The compounds may be synthesized by methods involving reductive annulations of arylidene malonates with unsaturated electrophiles using photoredox/Lewis acid cooperative catalysis. The compounds may be formulated in a pharmaceutical composition for treating one of the aforementioned diseases or disorders.

Abstract: A lubricant composition includes a base lubricant and a plurality of lubricant additive molecules functioning as precursor molecules to induce tribopolymerization and forming in situ protective tribofilm with desirable robustness and low shear resistance. Each lubricant additive molecule includes one or more surface-active groups attractable to target surface, and a carbon containing component operable connected to the one or more surface active groups. The carbon containing component comprise a carbon ring structure having a high ring strain that is metastable and activatable with a ring-opening reaction. A less stable carbon ring structure is more readily activated to the intermediate state, preferable to form more active fragments. Increasing the adsorption strength further is beneficial to prolonging the residence time of additive molecules on the target surface, thereby facilitating the dissociation of molecules and subsequent polymerization.

Abstract: The present invention relates to compositions and methods for delivering an oligonucleotide-functionalized nanoparticle.